Statins induce biochemical changes in the Achilles tendon after chronic treatment  by de Oliveira, Letícia Prado et al.
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Statins  have been  widely  prescribed  as lipid-lowering  drugs  and  are  associated  with  tendon  rupture.
Therefore,  this  study  aimed  to evaluate  the  possible  biochemical  changes  in  the  Achilles  tendon  of  rats
after  chronic  treatment  with  statins.  Dosages  of  statins  were  calculated  using  allometric  scaling  with
reference  to the  80 mg/day  and  20  mg/day,  doses  recommended  for humans.  The  rats  were  divided  into
the following  groups:  treated  with  simvastatin  (S-20  and  S-80),  treated  with  atorvastatin  (A-20  and  A-
80),  and the  control  group  that  received  no treatment  (C).  Measurements  of  low-density  lipoprotein
(LDL)  in  the  plasma  were  performed.  The  levels  of non-collagenous  proteins,  glycosaminoglycans  (GAGs)
and  hydroxyproline  were quantiﬁed.  Western  blotting  for collagen  I  was  performed,  and  the  presence  of
metalloproteinases  (MMPs)-2  and  -9 was  investigated  through  zymography.  The  concentration  of  non-
collagenous  proteins  in  S-20  was  less  than  the C group.  There  was a signiﬁcant  increase  in pro-MMP-2
activity  in  A-80  group  and in active  MMP-2  in  S-20  group  compared  to  the C  group.  A  signiﬁcant  increase
in  latent  MMP-9  activity  was observed  in  both  the  A-80  and S-20  groups  when  compared  to  C  group.
In the  A-20  group,  there  was  a lower  amount  of  collagen  I in  relation  to C  group.  In  addition,  a higher
concentration  of  hydroxyproline  was  found  in the  S-20  group  than  the  C group.  The  analysis  of  GAGs
showed  a signiﬁcant  increase  in  the  A-20  group  when  compared  to  C  group.  The  treatment  induced
remarkable  alterations  in the  Achilles  tendon  and  the response  of  the tissue  seems  to  depend  of  the
used  statin  dosage.  The  presence  of  MMP-2  and  MMP-9  is evidence  of the  degradation  and  remodeling
processes  in  the extracellular  matrix  of the  tendons.  Our  results  show  that statins  induce  imbalance  of
ponenextracellular  matrix  com
. Introduction
Statins are a group of drugs prescribed for the treatment
f hyperlipidemia, and they act by inhibiting 3-hydroxy-3-
ethylglutaryl-coenzyme A (HMG-CoA) reductase, an enzyme
nvolved in cholesterol production. HMG-CoA reductase catalyzes
he conversion of HMG-CoA to mevalonate, and therefore serves as
 therapeutic target for the action of statins (Campo and Carvalho,
007). Consequently, HMG-CoA reductase inhibitors induce a
eduction of LDL in the plasma, a reduction of intracellular choles-
erol and an increase of the LDL receptors (Maron et al., 2000).
Statins are widely prescribed medications with various clinical
eneﬁts, including the prevention of myocardial infarction and the
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formation of atherosclerotic plaques (O’Sullivan, 2007). Addition-
ally, many studies have shown that the clinical beneﬁts associated
with statins are either independent of or indirectly dependent on
a reduction in LDL-cholesterol (Campo and Carvalho, 2007). These
pleiotropic effects, have been well-studied in an effort to identify
additional potential uses for these drugs in the treatment of other
pathologies, such as (Liao and Laufs, 2005) hypertension, (Yang
et al., 2005), Alzheimer’s disease (Campo and Carvalho, 2007), sep-
sis (Giusti-Paiva et al., 2004) and osteoporosis (Jadhav and Jain,
2006).
Despite being quite effective medicines, statins have some
adverse effects, including constipation, headaches, sleep distur-
bances, and other more serious effects, such as hepatotoxicity and
musculoskeletal complications (Hoffman et al., 2012; O’Sullivan,
2007). More recently, cases of tendinitis and tendon ruptures have
been associated with the use of statins (Marie and Noblet, 2009).
These complications have been observed in several tendons, includ-
ing the distal biceps (Savvidou and Moreno, 2012), the patellar (Beri
et al., 2009), the quadriceps (Nesselroade and Nickels, 2010; Rubin
et al., 2011) and the Achilles tendons (Beri et al., 2009; Carmont
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t al., 2009; Chazerain et al., 2001), the latter of which are com-
only injured (Marie et al., 2008).
Simvastatin and atorvastatin are some of the most widely
sed statins in the treatment of hypercholesterolemia, and they
re highly efﬁcacious and tolerable (Maron et al., 2000). How-
ver, they can also result in tendinopathies (Marie et al., 2008).
endinopathies seem to be a rare adverse effect of statins, but it
s also thought that many of these types of adverse effects are left
nreported to pharmacovigilance centers (Chazerain et al., 2001).
Recent studies have shown that statins are responsible for
nhibiting the secretion of metalloproteinases (MMPs) in lung
broblasts (Kamio et al., 2010) and endothelial cells (Izidoro-Toledo
t al., 2011). Furthermore, they reduce the expression of collagen
 in smooth muscle (Schaafsma et al., 2011). Of note, tendons are
ormed primarily by collagen I, and MMPs  play an important role
n maintaining and remodeling the extracellular matrix in tendons
Kannus, 2000).
In addition to lowering cholesterol and inhibiting MMPs
Izidoro-Toledo et al., 2011), statin use has also been shown to
romote apoptosis in ﬁbroblasts (Yokota et al., 2008), further sug-
esting an association between statin use and tendon rupture.
ogether, these factors can weaken the integrity of the tendon
issue and thus predispose the tendon to rupture.
Statins are widely prescribed drugs, and investigating the
iochemical changes in tendons caused by statins may  help to
nderstand the causes of tendinitis and tendon rupture associ-
ted with the use of those drugs. Because there are no studies that
ddress the effects of statins on the components of the extracellu-
ar matrix in tendons, this study was designed to investigate the
ffects of chronic oral statin treatment on the Achilles tendon in
ats.
. Methods
.1. Experimental groups
Animal care was in accordance with the European Convention for the Protection
f  Vertebrate Animals used for Experimental and Other Scientiﬁc Purposes and was
onsistent with the ethical principles of animal experimentation adopted by the
razilian College of Animal Experimentation (COBEA), was  approved by the Ethics
ommittee on Animal Experiments of State University of Campinas, SP, Brazil and
led under no. 2473-1.
We used 50 male Wistar rats, young adults, weighing on average 300 g. The rats
ere housed two per cage in a 12 h light:dark cycle at 23 ◦C, with free access to
tandard rat chow and water.
The animals were divided into ﬁve experimental groups: rats treated with a daily
ose equivalent to 20 mg  of atorvastatin (pharmanostra, Rio de Janeiro, Brazil) (A-
0) or simvastatin (Galena, Campinas, Brazil) (S-20), rats treated with a daily dose
quivalent to 80 mg  of atorvastatin (A-80) or simvastatin (S-80) and the control
roup that received no treatment (C). To dilute the statins we  used an aqueous
olution of 0.5% carboxymethylcellulose. The treatment lasted for 2 months and a
avage was used to administer the solutions (Camerino et al., 2011).
We  accounted for the metabolic rate of the animals and used allometric scaling
o  calculate the necessary drug dosage (Pachaly and Brito, 2001). Thus, it was neces-
ary  to use an animal model in which the pharmacokinetic and pharmacodynamics
arameters of the drug of interest were known. In this study, we used as animal
odel the human and animal target Wistar rats. After two  months of treatment, the
nimals were euthanized with isoﬂurane (Isofurine – Cristália, Itapira, Brazil) and
he tendons were collected for biochemical analysis.
.2. LDL-cholesterol determination
For the determination of LDL-cholesterol in the plasma of the rats an enzymatic
ssay was  used. Through this assay it is possible to measure LDL-cholesterol directly
Kit LDL-C Plus-Roche).
.3. Extraction proceduresThe calcaneal tendon (n = 5) was cut in small pieces and treated with 50 volumes
f 4 M guanidine hydrochloride (GuHCl) containing 20 mM EDTA, 1 mM PMSF in
0 mM sodium acetate buffer, pH 5.8, for 24 h at 4 ◦C with mild stirring (Heinergard
nd  Sommarin, 1987). Afterwards, the material was centrifuged (13,000 × g, 25 min,y 311 (2013) 162– 168 163
4 ◦C) and the supernatant was used for non-collagenous protein dosage and Western
blotting for collagen I.
2.4. Quantiﬁcation of proteins
Samples of the extracts of each experimental group were used. Non-collagenous
proteins (NCPs) were quantiﬁed according to the Bradford method (1976),  using
bovine serum albumin as standard. The absorbance was measured at 595 nm.
2.5. Hydroxyproline quantiﬁcation
After washing in PBS (phosphate-buffered saline—5 mM phosphate buffer,
0.15 M NaCl and 50 mM EDTA), fragments from the tendons were immersed into
acetone for 48 h and then into chloroform:ethanol (2:1) for 48 h. Fragments were
weighed and hydrolyzed in 6 N HCl (1 mL  for each 10 mg  of tissue) for 16 h at 110 ◦C.
The hydrolysate was  neutralized with 6 N NaOH, and 20 L of each sample was
treated with chloramine T solution, as described by Stegemann and Stalder (1967)
and Jorge et al. (2008), with some modiﬁcations. The absorbance was measured at
550  nm in a spectrophotometer. Hydroxyproline concentrations from 0.2 to 6 g/mL
were used for a standard curve.
2.6. Agarose gel electrophoresis
The fragments of the tendons were dehydrated, and sulfated glycosaminogly-
cans were released from proteoglycans by digestion with a papain solution (Merck,
Darmstadt, Germany) (40 mg/g of dry tissue) containing 100 mM sodium phosphate
buffer, pH 6.5, 40 mM EDTA, and 80 mM -mercaptoethanol (Harab and Morão,
1989). The reaction was stopped by the addition of 4 mM iodoacetic acid for 1 h.
The  sulfated GAGs were precipitated in ethanol and separated by agarose gel elec-
trophoresis (0.6%) in 0.05 M propylenediamine according to Dietrich and Dietrich
(1976).
2.7. Quantiﬁcation of sulfated GAGs
The samples digested by papain solution were used to quantify the GAGs of the
tendons of the different experimental groups. The quantiﬁcation was determined
using the dimethylmethylene blue method (Farndale et al., 1986) using chondroitin
sulfate as the standard. The absorbance was measured at 540 nm using an Asys
Expert Plus Microplate Reader (Biochrom, Holliston, MA,  USA).
2.8. Western blotting for collagen I
For collagen I detection, were precipitated 10 g of total protein from the guani-
dine extract, using a solution containing 1 M sodium acetate buffer pH 7.4 (100 mL)
and 9 volumes of ethanol (1350 mL) for 24 h at 4 ◦C. After three washes (150 mL
acetate buffer 1 M sodium pH 7.4 and 1350 mL of ethanol), the precipitate obtained
was dried at 37 ◦C and resuspended in reducing sample buffer (0.5 M Tris–HCl pH
6.8, 26% glycerol, 20% SDS, 0.1% Bromophenol Blue). Proteins tendon subjected
to  electrophoresis on SDS-polyacrylamide (6%) were transferred to nitrocellulose
membrane, as described by Towbin et al. (1979).
The membranes were transferred to the device Snap i.d. (Millipore, Billerica,
USA). They were blocked with BlØk-CH reagent for 15 s and then the membranes
were incubated with primary antibody (C2456 – Sigma–Aldrich for collagen I)
at  a dilution of 1:500 for 10 min. The membranes were washed three times in
TBS. Incubation with secondary antibody (A8786 – anti-mouse Sigma–Aldrich and
A2306 – anti-rabbit Sigma–Aldrich) was performed for 10 min  and washed again.
The  revelation was performed with DAB (dimethylaminobenzaldehyde). The band
densitometry was made using the Scion Image software Alpha 4.0.3.2 (Scion Corpo-
ration).
2.9. Zymography
Metalloproteinase analyses were made according to Marqueti et al. (2006).  The
samples were incubated in extraction buffer (Tris–HCl 50 mM pH 7.4, NaCl 0.2 M,
Triton X-100 0.1%, CaCl2 10 mM and protease inhibitor 100 L/10 mL)  at 4 ◦C for
24  h. For MMP-2 and MMP-9 analysis were applied 20 g of proteins in each lane
of  sodium dodecyl sulfate (SDS) – 10% polyacrylamide gels prepared with 2 mg/mL
gelatin. Then, the gel was incubated in incubation buffer (Tris–HCl 50 mM pH 8.4,
5  mM de CaCl2 e 1 M de ZnCl2) overnight at 37 ◦C. Gels were stained with Coomassie
Brilliant Blue R-250 and bleached (methanol solution 30% and 10% acetic acid in
water). Finally, the gel was placed in shrinking solution (30% methanol and 3% glyc-
erol). The band densitometry was  made using the Scion Image software Alpha 4.0.3.2
(Scion Corporation).
2.10. Statistical analysisAll results were expressed as mean ± standard deviation. The results were ana-
lyzed by analysis of variance (ANOVA-one-way) followed by Tukey test. The level
of  signiﬁcance was p < 0.05. The analysis was carried out in GraphPad Prism 3.0
program. It was  used n = 5 for each technique.
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Fig. 1. Plasma levels of LDL-cholesterol (mg/dL) in the different groups. There are
no  signiﬁcant differences between the groups, but all groups treated with statins
had  a tendency toward reduction of LDL-cholesterol. (A) atorvastatin; (C) control;
(S) simvastatin.
Fig. 2. Concentration of non-collagenous proteins (mg/g wet  tissue) in the different
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Fig. 3. Concentration of hydroxyproline (mg/g dry tissue) in the different groups. A
high concentration was detected in group S-20 compared to the C group. (a) p < 0.05
relative to C. (A) atorvastatin; (C) control; (S) simvastatin.
Fig. 4. Concentration of sulfated glycosaminoglycans (mg/g dry tissue) in the dif-
ferent groups. In group A-20, there are higher concentrations of GAGs compared to
the C group. A smaller amount of GAGs was observed in groups that received statins
The individual GAGs were analyzed using agarose gels androups. The S-20 group had smaller amounts of non-collagenous proteins compared
o  the C group. (a) p < 0.05 relative to C. (A) atorvastatin; (C) control; (S) simvastatin.
. Results
Biochemical analyses were performed on Achilles tendon
xtracts and LDL was determined in the plasma of the rats after
wo months of treatment with atorvastatin or simvastatin.
.1. LDL-cholesterol determination
LDL-cholesterol dosage was made to evaluate the biological
ffect of the statins (Fig. 1). Although we do not ﬁnd signiﬁcant
ifferences between the groups, it was observed a reduction of LDL
holesterol in plasma of rats treated with statins when compared
o the control group.
.2. Quantiﬁcation of proteins
The quantiﬁcation of non-collagenous proteins allowed obtain-
ng the concentration of total non-collagenous proteins in the
xtracts of the tendons. There was a signiﬁcant reduction in non-
ollagenous proteins in the S-20 group relative to the C group
Fig. 2).
.3. Hydroxyproline quantiﬁcationThe quantiﬁcation of hydroxyproline (Fig. 3), which indirectly
easures the total collagen content in the tissue (mg/g dry weight),equivalent to 80 mg/day. (a) p < 0.05 relative to C; (b) p < 0.05 between the A-20 and
the  A-80 groups; (c) p < 0.05 between the S-20 and S-80 groups. (A) atorvastatin; (C)
control; (S) simvastatin.
revealed a signiﬁcant increase in the S-20 group compared to the C
group.
3.4. Quantiﬁcation of sulfated GAGs
The total amount of GAGs in the Achilles tendon was mea-
sured (Fig. 4) and there was  a signiﬁcant increase in GAGs in
the A-20 group compared to the C group. Statistical analysis also
revealed differences between the A-20 group and the A-80 group
and between the S-20 group and the S-80 group; there were lower
levels of GAGs in the groups that received dosage equivalent to
80 mg/day relative to those that received dosage equivalent to
20 mg/day.
3.5. Agarose gel electrophoresisshowed the presence of dermatan sulfate in all groups (Fig. 5). Den-
sitometric analysis of the bands showed no signiﬁcant differences
(data not shown).
L.P. de Oliveira et al. / Toxicolog
Fig. 5. Agarose gel electrophoresis. HS (heparan sulfate), DS (dermatan sulfate), and
CS  (chondroitin sulfate) standards are shown on the left. No difference was detected
between the groups after 2 months of treatment. (A) atorvastatin; (C) control; (S)
simvastatin.
Fig. 6. (A) Western blotting for collagen I. Collagen I is found in all of the groups.
(B)  Densitometry of the bands corresponding to collagen type I of the groups. (a)
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g < 0.05 relative to (C); group A-20 had less type I collagen compared to the C group.
hen compared to the C group, all of the groups treated with statins had a tendency
oward reduction of type I collagen. (A) atorvastatin; (C) control; (S) simvastatin.
.6. Western blotting for collagen I
Western blotting for collagen I (Fig. 6A) allowed analyzing
peciﬁcally the collagen I, the major component of the tendon.
ccording to the results observed, the A-20 group had a smaller
and than other groups; densitometric analysis of the bands
Fig. 6B) revealed a statistically signiﬁcant reduction of collagen
 in the A-20 group compared to the C group.
.7. Zymography
The isoforms of the enzymes MMP-2 and MMP-9 were analyzed
y zymography. The presence of latent MMP-9 and active MMP-9
as detected in all of the groups except for the C group (Fig. 7A).
ensitometric analysis of the bands (Fig. 7B) showed that groups
-80 and S-20 had signiﬁcantly more latent MMP-9 relative to the C
roup. The A-20 group showed a signiﬁcant increase in the activity
f the active MMP-9 compared to the C group. Although no signiﬁ-
ant differences were found among other groups, it is noteworthy
hat there was an increase in the activities of active MMP-9 in all
f the groups treated with statins.Both active MMP-2 and pro-MMP-2 were observed in all of the
roups (Fig. 7). The densitometric analysis of the bands (Fig. 7C)
howed a signiﬁcant increase in activity of pro-MMP-2 in the A-80
roup and active MMP-2 in the S-20 group relative to the C group.y 311 (2013) 162– 168 165
4. Discussion
Statins belong to a class of drugs prescribed for the treatment
of dyslipidemia. These drugs are effective and relatively safe with
few adverse effects (O’Sullivan, 2007). However, there have been
reports of tendon complications because of statin therapy (Beri
et al., 2009; Carmont et al., 2009; Marie et al., 2008; Nesselroade
and Nickels, 2010; Pullatt et al., 2007). This is the ﬁrst report in
the literature showing the effect of the different doses of statins in
the tendon of rats. Therefore, in this study, we analyzed the possi-
ble biochemical changes in the Achilles tendon of rats after chronic
treatment with simvastatin or atorvastatin.
In this work, allometric scalling was used to calculate de appro-
priate dosage of drug to administer to the rats to mimic  the dosage
administered in man  (Pachaly and Brito, 2001). In humans, phar-
macokinetic and pharmacodynamic parameters of statins are well
established. The dosages of 20 mg/day and 80 mg/day were deter-
mined because they correspond to the minimum and maximum
dosages, respectively, employed in human therapy (Goodman and
Gilman, 2006).
Statins are the most effective drugs for reducing LDL-cholesterol
levels (Maron et al., 2000). In this study the determination of LDL-
cholesterol was made to evaluate the biological effect of the statins.
Although we  do not ﬁnd signiﬁcant differences in the determina-
tion of LDL-cholesterol, trend toward a reduction of this lipoprotein
in all of the groups treated with statins when compared to the con-
trol group was observed. Hyperlipidemia was  not induced in the
rats used in this study, and therefore, it was expected that lower-
ing LDL-cholesterol levels would not be so pronounced, considering
that the ratio of LDL-cholesterol in the plasma of normal rats is low
(Sanchez-Muniz and Bastida, 2008).
Extracellular matrix of the tendons contain various non-
collagenous proteins and their function are related with stabilizing
collagen ﬁbers, considering that these proteins seem to have
a property to bind to other macromolecules or in cell surface
(Kannus, 2000; Partington and Wood, 1963). After treatment
with statins, there was  a signiﬁcant reduction in the levels of
non-collagenous proteins in the tendons of the S-20 group, thus
indicating a protein degradation or reduced protein synthesis in
tenocytes. In fact, there is an increase in protein degradation asso-
ciated with tendon irregularities (Karousou et al., 2008; Vieira
et al., 2012). Non-collagenous proteins were reduced in inﬂamed
tendons (Vieira et al., 2012). Probably the degradation of the non-
collagenous proteins may  be increased due to treatment with
simvastatin.
MMPs  are enzymes that participate in the maintenance of tis-
sue homeostasis of various organs (Malemud, 2006). The presence
of MMP-2 and MMP-9 are signs of degradation and matrix remod-
eling, and if their activities are not properly regulated, the integrity
of the tissue can be affected, which makes the tendon more sus-
ceptible to injury (Karousou et al., 2008). It has been reported that
various statins inhibit the expression of MMPs, an effect mediated
by a reduction in the intermediates of the HMG-CoA reductase
pathway, such as the isoprenoid farnesyl pyrophosphate and ger-
anylgeranyl pyrophosphate, These intermediates are important in
the post-translational modiﬁcation of proteins such as Rho, which
is present in signaling pathway for the secretion of MMPs  (Barter
et al., 2010; Kamio et al., 2010; Turner et al., 2005). Nevertheless, in
our study, we found an increase of pro-MMP-2 and active MMP-2 in
the A-80 and S-20 groups, respectively. These groups also showed
a signiﬁcant increase in latent MMP-9. In vitro experiments con-
ducted by Lee et al. (2012) demonstrated that atorvastatin and
simvastatin can increase the expression of MMP-9 in macrophages,
thereby increasing the phosphorylation of MAP  kinases that are
involved in the signaling pathway mediated by lipopolysaccha-
rides. Thus, depending on the cell signaling pathway and tissues
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Fig. 7. (A) Zymography for analysis of MMP-2 and MMP-9. Observe the presence of latent MMP-9 (92 kDa) and active MMP-9 (83 kDa) in the A-20, A-80, S-20 and S-80
groups. All groups studied show pro-MMP-2 (72 and 68 kDa) and active MMP-2 (62 kDa). (B) Densitometry of the bands corresponding to the MMP-9 isoforms. The activity
of  the latent MMP-9 is elevated in the A-80 and S-20 groups; a higher value was observed for the active MMP-9 in the A-20 group compared to the C group. (C) Densitometry
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n  the S-20 group. (a) p < 0.05 relative to C. (A) atorvastatin; (C) control; (S) simvast
nvolved, these drugs appear to exert different effects on the activ-
ty of MMPs.
The active isoform of MMP-9 is generally involved in inﬂam-
atory processes and tendon rupture. In these cases, there is an
ncrease in the expression of MMP-9 (Jones et al., 2006). The A-20
roup showed a pronounced increase of this enzyme in compari-
on to the C group. Although we did not ﬁnd signiﬁcant differences
n the remaining groups that received statins, both latent MMP-9
nd active MMP-9 were present. An excess of MMPs  proteolytic
ctivities can lead to progressive tendon degeneration, weakening
f the tendon extracellular matrix, and a consequent reduction in
he biomechanical properties of the tendon (Karousou et al., 2008).
hus, based on the proﬁle of MMPs  found in our study, an inﬂam-
atory process may  have been induced by statin treatment that
etrimentally affected the integrity of the tendon.
Hydroxyproline is a major component of the collagen (Neuman
nd Logan, 1950). Our results showed an increase in hydroxypro-
ine in the S-20 group, which is consistent with the analyses of
otal collagen content in patellar tendinopathy, in which greater
mounts of hydroxyproline in lesion regions have been observed
Samiric et al., 2009). The highest concentration of hydroxyproline
as found in the S-20 group and may  be a result of an increase in
ollagen fragments resulting from the increased activity of MMPs-2
nd -9 (Vieira et al., 2012). Furthermore, if statins caused injuries to
he tendons analyzed in this study, it was expected that tenocytes
ould synthesize more collagen to restore the normal composition
f the tendons. In the collagen I analysis, the S-20 group showed a
eduction of this component. Probably, tendon cells may  have syn-
hesized other types of collagen in greater amounts than collagen
, in response to tendon damage (Thomopoulos et al., 2002). Thus,
his may  be an explanation for the higher content of hydroxyproline
nd the reduction of collagen I founded in the S-20 group.
Although only the A-20 group showed a signiﬁcant reduction in
ollagen I, trend toward a reduction in collagen I in the remaining0 group when compared to the C group and active MMP-2 shows increased activity
groups that received statins was observed. Morphological analysis
of atherosclerotic plaques performed by Cherpachenko et al. (2009)
showed a decrease in collagen ﬁbers in the plaques of patients who
used statins for the treatment of hyperlipidemia. In another study,
it was found that simvastatin inhibited the synthesis of collagen I in
smooth muscle cells, an effect that is closely related to the reduction
of intermediate isoprenoids in the cholesterol synthesis pathway
(Schaafsma et al., 2011). Therefore, our results suggest that atorvas-
tatin was mainly responsible for drastically inhibiting the synthesis
of type I collagen in tendon. Type I collagen is the major extracel-
lular matrix component of tendons; it forms highly oriented ﬁbrils
that confer the tensile strength of this tissue (Gelse et al., 2003).
Therefore, any imbalance between collagen synthesis and degra-
dation may  weaken the tissue and thereby predispose the tendon
to microdamage and ruptures (Riley et al., 2002).
As mentioned previously, in the A-20 group, MMP-9 showed
augmented activity; therefore, the reduction of collagen type I
found in the same group may  be due to the proteolytic activity of
this enzyme. It is important to note that collagen I is one of the sub-
strates of the MMP-9 and that this enzyme degrades fragments of
collagen after tendon rupture (Chakraborti et al., 2003; Riley et al.,
2002).
There are no reports that statins may  directly affect the synthe-
sis of GAGs. However, in our study, we observed a greater amount
of sulfated glycosaminoglycans in the A-20 group relative to the
C group. It is possible that the increased MMPs  found in the A-
20 group caused degradation of the collagen, thereby inducing
the tenocytes to synthesize more glycosaminoglycans to assist in
the repair process. A biochemical analysis of patellar tendons in
chronic degenerative processes showed an increase in the synthe-
sis and deposition of GAGs compared to normal tendons (Samiric
et al., 2009). Thus, our results suggest that treatment with atorvas-
tatin may  be involved in chronic disorders of tendons. Until now
there is no explanation for the signiﬁcant differences in content of
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AGs found between the A-20 group and the A-80 group and also
etween the S-20 group and the S-80 group.
When administered orally, statins undergo intensive ﬁrst-pass
etabolism in the liver, and a small proportion of the adminis-
ered dose is accumulated in extra-hepatic tissues (Blum, 1994;
orsini et al., 1999). Despite having a low systemic bioavailability
Schachter, 2004), our results suggest that these drugs were active
n the tendons and that the chronic use of the statins may  cause
etrimental changes to the extracellular matrix of the tendon.
The ﬁndings of this study suggest that there is a possible reverse
ffect when we analyzed the dose equivalent to 80 mg.  Possibly
arger doses caused tendon injuries in the initial period of the treat-
ent (ﬁrst few weeks), while lower doses caused lesions late onset,
r after a longer period of statin administration (2 months). This
xplains the results obtained for the groups treated with a dose
quivalent to 20 mg.  Furthermore, statins have pleiotropic effects
hich are widely studied (Farmer, 2000; Liao and Laufs, 2005). It
as been shown that statins can promote recovery from a tissue that
as suffered an injury, for example, skin (Rego et al., 2007; Toker
t al., 2009) and bone (Skoglund and Aspenberg, 2007; Wang et al.,
007). So, it is possible that initially, the administration of statins
aused an injury in the normal tendon. Then, after that initial lesion,
he same drug, administered chronically may  have acted recover-
ng this tendon. This may  be a hypothesis to explain the possible
eversed results founded in the groups treated with dosage equiv-
lent to 80 mg.  If analyzes were performed in periods exceeding
 months of treatment, it is possible that the reverse effects also
ould be observed at a dose equivalent to 20 mg  which takes longer
ime to act.
Although apparently there is a reverse effect on the dose equiva-
ent to 80 mg,  it is important to note that initially both doses caused
hanges in the extracellular matrix of tendons. The presence of
ctive MMP-9 in all of the groups treated with statins is a strong evi-
ence of tendon injury. Furthermore, a tendon that suffers an injury
ever completely regains the biomechanical properties it had prior
o injury (James et al., 2008).
. Conclusions
Finally, our results clearly suggest that statins cause remark-
ble changes to the extracellular matrix of the Achilles tendon. The
esponse of the tendon to the treatment is different depending on
he dose and type of statin used. The presence of MMP-2 and MMP-
 suggest that the degradation and remodeling of the extracellular
atrix were triggered. Our results provide evidence indicating that
tatins promote an imbalance between the synthesis and degra-
ation of several molecules, particularly collagen I, and possibly
nduce microdamage in the tendons. Therefore, it is necessary to
onitor all patients using statins, especially those who have ten-
on complications or those that have potential risk of developing
endinopathy.
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